Roberto Furlan - Neurology

Author Information

Roberto Furlan is affiliated with the Institute of Experimental Neurology, Division of Neuroscience, at the San Raffaele Scientific Institute in Milan, Italy. His research primarily focuses on the neurological domain, with a particular interest in neuroinflammation, multiple sclerosis, and the impact of biomarkers on neurological diseases.

Research Contributions

Roberto Furlan has made significant contributions to the field of neurology, with numerous publications that explore various aspects of neurological disorders. In 2022, his research covered topics such as neuroinflammation and its association with biomarkers like GFAP and sTREM2 in multiple sclerosis, as well as the impact of genetic polymorphisms on inflammation in the disease's early phases. His work also includes investigating predictive biomarkers for multiple sclerosis relapses, the effects of storage on extracellular vesicles, and cognitive vulnerability in depressed COVID-19 survivors. Additionally, he has contributed to understanding the diagnosis and prognosis of amyotrophic lateral sclerosis through neurochemical biomarkers.

Aliases

Roberto Furlan is also known by the aliases R Furlan and R. Furlan, as reflected in various academic publications and references.

Publication and Citation Metrics

Citation Count	15,365
h-index	64
Paper Count	304

Publications:

Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis

DOI: 10.3390/biom12020222

Year: 2022

The BDNF Val66Met Polymorphism (rs6265) Modulates Inflammation and Neurodegeneration in the Early Phases of Multiple Sclerosis

DOI: 10.3390/genes13020332

Year: 2022

High or increasing serum NfL is predictive of impending multiple sclerosis relapses.

DOI: 10.1016/j.msard.2022.103535

Year: 2022

The impact of storage on extracellular vesicles: A systematic study

DOI: 10.1002/jev2.12162

Year: 2022

Mood-congruent negative thinking styles and cognitive vulnerability in depressed COVID-19 survivors: A comparison with major depressive disorder

DOI: 10.1016/j.jad.2022.04.077

Year: 2022

Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in Amyotrophic Lateral Sclerosis.

DOI: 10.1111/ene.15321

Year: 2022

Neutrophil-to-lymphocyte ratio: a marker of neuro-inflammation in multiple sclerosis?

DOI: 10.1007/s00415-020-10322-7

Year: 2021

Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis

DOI: 10.1002/ana.26154

Year: 2021

CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study

DOI: 10.1186/s10020-021-00390-4

Year: 2021

Higher baseline interleukin-1β and TNF-α hamper antidepressant response in major depressive disorder

DOI: 10.1016/j.euroneuro.2020.11.009

Year: 2021

What are Environmental Factors in Neurology?

What is the Prognosis for Parkinson's Disease?

What is the Recovery Process Like?

What is a Neuropsychological Assessment?

What Do EEG Results Mean?

What is Chronic Fatigue Syndrome (CFS)?

How is PRMS Different from Other Forms of MS?

What are the Risks and Complications?

What are the Limitations of Oligoclonal Band Testing?

How Does Tourette Syndrome Affect Daily Life?

Partnered Content Networks

Relevant Topics